Evidence map›Paper›PMID 24949720›Full record

ArticlePloS one2014

mTORC2 phosphorylation of Akt1: a possible mechanism for hydrogen sulfide-induced cardioprotection.

Yue Zhou, Daying Wang, Xiufang Gao, Karsheng Lew, Arthur Mark Richards, Peipei Wang

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Recent Advances in Molecular Research on Hydrogen Sulfide (HInternational journal of molecular sciences · 2022
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. ArrhythmoGenoPharmacoTherapy.Frontiers in pharmacology · 2020
    Review
  12. Article
  13. Review
  14. Review
  15. Hydrogen Sulfide (HFrontiers in pharmacology · 2018
    Review
  16. Review
  17. Emerging role of hydrogen sulfide-microRNA crosstalk in cardiovascular diseases.American journal of physiology. Heart and circulatory physiology · 2016
    Review
  18. Article
  19. Article
  20. Role of Hydrogen Sulfide in Ischemia-Reperfusion Injury.Oxidative medicine and cellular longevity · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yue ZhouCardiovascular Research Institute, National University of Singapore, Singapore, Singapore.
Daying WangDepartment of Cardiology, Putuo Hospital, Shanghai, China.
Xiufang GaoDepartment of Cardiology, Huashan Hospital, Fudan University, Shanghai, China.
Karsheng LewCardiovascular Research Institute, National University of Singapore, Singapore, Singapore.
Arthur Mark RichardsCardiovascular Research Institute, National University of Singapore, Singapore, Singapore.
Peipei WangCardiovascular Research Institute, National University of Singapore, Singapore, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrogen sulfide (H2S) is known to have cardiac protective effects through Akt activation. Akt acts as a 'central sensor' for myocyte survival or death; its activity is regulated by multiple kinases including PI3K, mTORC2, PDK1 and phosphatases including PTEN, PP2A and PHLPPL. Based on the previous finding that PI3K inhibitor LY294002 abolishes H2S-induced Akt phosphorylation and cardioprotection, it is accepted that PI3K is the mediator of H2S-induced Akt phosphorylation. However, LY294002 inhibits both PI3K and mTOR, and PI3K only recruits Akt to the membrane where Akt is phosphorylated by Akt kinases. We undertook a series of experiments to further evaluate the role of mTORC2, PDK1, PTEN, PP2A and PHLPPL in H2S-induced Akt phosphorylation and cardioprotection, which, we believe, has not been investigated before. Hearts from adult Sprague-Dawley rats were isolated and subjected to (i) normoxia, (ii) global ischemia and (iii) ischemia/reperfusion in the presence or absence of 50 µM of H2S donor NaHS. Cardiac mechanical function and lactate dehydrogenase (LDH) release were assessed. All hearts also were Western analyzed at the end of perfusion for Akt and a panel of appropriate Akt regulators and targets. Hearts pretreated with 50 µM NaHS had improved function at the end of reperfusion (Rate pressure product; 19±4×10(3) vs. 10±3×10(3) mmHg/min, p<0.05) and reduced cell injury (LDH release 19±10 vs. 170±87 mU/ml p<0.05) compared to untreated hearts. NaHS significantly increased phospho-Akt, phospho-mTOR, phospho-Bim and Bcl-2 in reperfused hearts (P<0.05). Furthermore using H9c2 cells we demonstrate that NaHS pretreatment reduces apoptosis following hypoxia/re-oxygenation. Importantly, PP242, a specific mTOR inhibitor, abolished both cardioprotection and protein phosphorylation in isolated heart and reduced apoptotic effects in H9c2 cells. Treating hearts with NaHS only during reperfusion produced less cardioprotection through a similar mechanism. These data suggest mTORC2 phosphorylation of Akt is a key mediator of H2S-induced cardioprotection in I/R.

Indexed as

AnimalsCardiotonic AgentsChromonesHumansHydrogen SulfideMechanistic Target of Rapamycin Complex 2MorpholinesMultiprotein ComplexesMuscle CellsOrgan Culture TechniquesPhosphoinositide-3 Kinase InhibitorsPhosphorylationProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePyruvate Dehydrogenase Acetyl-Transferring Kinase2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAkt1 protein, ratCardiotonic AgentsChromonesHydrogen SulfideMechanistic Target of Rapamycin Complex 2MorpholinesMultiprotein ComplexesPDK1 protein, humanPdk1 protein, ratPhosphoinositide-3 Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePten protein, ratPyruvate Dehydrogenase Acetyl-Transferring KinaseTOR Serine-Threonine Kinases

Identifiers

PMID24949720
PMCPMC4064967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.